An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs BAY 1217389 (Primary) ; Paclitaxel
- Indications Breast cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 08 Sep 2017 Planned primary completion date changed from 27 Oct 2017 to 24 Nov 2017.
- 09 Aug 2017 Planned End Date changed from 21 Dec 2017 to 23 Feb 2018.
- 09 Aug 2017 Planned primary completion date changed from 31 Aug 2017 to 27 Oct 2017.